In-111 Zevalin Disease Interactions
There are 3 disease interactions with In-111 Zevalin (ibritumomab).
Ibritumomab tiuxetan (applies to In-111 Zevalin) cytopenia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve. It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.
References (1)
- "Product Information. In-111 Zevalin (ibritumomab tiuxetan)." IDEC Pharmaceuticals Corporation
Ibritumomab tiuxetan (applies to In-111 Zevalin) vaccination
Major Potential Hazard, Moderate plausibility.
The safety of immunization with live viral vaccines following the ibritumomab tiuxetan has not been studied. Do not administer live viral vaccines to patients who have recently received ibritumomab tiuxetan. The ability to generate an immune response to any vaccine following the therapeutic regimen has not been studied.
References (1)
- "Product Information. In-111 Zevalin (ibritumomab tiuxetan)." IDEC Pharmaceuticals Corporation
Ibritumomab tiuxetan (applies to In-111 Zevalin) hematological toxicity
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myelodysplastic Disease, Leukemia
The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
References (1)
- "Product Information. In-111 Zevalin (ibritumomab tiuxetan)." IDEC Pharmaceuticals Corporation
Switch to consumer interaction data
In-111 Zevalin drug interactions
There are 372 drug interactions with In-111 Zevalin (ibritumomab).
Report options
More about In-111 Zevalin (ibritumomab)
- In-111 Zevalin consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: CD20 monoclonal antibodies
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Bendamustine
Bendamustine systemic is used for chronic lymphocytic leukemia, multiple myeloma, non-hodgkin's lymphoma
Fludarabine
Fludarabine systemic is used for cancer, chronic lymphocytic leukemia, chronic myelogenous ...
Cytarabine
Cytarabine systemic is used for acute myeloid leukemia, acute nonlymphocytic leukemia, chronic ...
Vincristine
Vincristine systemic is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Cyclophosphamide
Cyclophosphamide systemic is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.